Induction Therapy with Bortezomib-Cyclophosphamide-Dexamethasone (BCD) for Newly Diagnosed Transplant Eligible Patients with Multiple Myeloma

被引：0
|
作者：
Tsukada, Nobuhiro [1 ]
Ikeda, Masahiro [1 ]
Shingaki, Sumito [1 ]
Miyazaki, Kanji [1 ]
Meshitsuka, Sosuke [1 ]
Abe, Yu [1 ]
Yoshiki, Yumiko [1 ]
Suzuki, Kenshi [1 ]
机构：
[1] Japanese Red Cross Med Ctr, Div Hematol, Tokyo, Japan
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2015年 / 21卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2014.11.313
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
270
引用
收藏
页码：S205 / S205
页数：1
相关论文
共 50 条
  • [31] Lenalidomide, Bortezomib, and Dexamethasone (RVD) As Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)
    Joseph, Nisha
    Almaula, Dhwani
    Gleason, Charise
    Heffner, Leonard
    Boise, Lawrence H.
    Kaufman, Jonathan L.
    Lonial, Sagar
    Nooka, Ajay
    BLOOD, 2017, 130
  • [32] Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
    Richardson, Paul G.
    Weller, Edie
    Lonial, Sagar
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Raje, Noopur S.
    Avigan, David E.
    Xie, Wanling
    Ghobrial, Irene M.
    Schlossman, Robert L.
    Mazumder, Amitabha
    Munshi, Nikhil C.
    Vesole, David H.
    Joyce, Robin
    Kaufman, Jonathan L.
    Doss, Deborah
    Warren, Diane L.
    Lunde, Laura E.
    Kaster, Sarah
    DeLaney, Carol
    Hideshima, Teru
    Mitsiades, Constantine S.
    Knight, Robert
    Esseltine, Dixie-Lee
    Anderson, Kenneth C.
    BLOOD, 2010, 116 (05) : 679 - 686
  • [33] Efscalefect of lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy in transplant-eligible patients (Pts) with newly diagnosed multiple myeloma (MM) on CR rates and survival.
    Gleason, Charise
    Nooka, Ajay K.
    Muppidi, Samatha
    Heffner, Leonard T.
    Steuer, Conor E.
    Kumar, Mukesh
    Casbourne, Daniela
    Langston, Amelia A.
    Watson, Melanie
    Boise, Lawrence
    Kaufman, Jonathan L.
    Lonial, Sagar
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] Bortezomib plus dexamethasone as induction therapy in newly diagnosed multiple myeloma: A preliminary study in thai patients
    Nakorn, T. Na
    Watanaboonyongcharoen, P.
    Niparuck, P.
    Chancharunee, S.
    Intragumtomchai, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 411 - 411
  • [35] Bortezomib-Dexamethasone vs Bortezomib-Dexamethasone and chemotherapeutic agents in Transplant-Eligible Newly Diagnosed Myeloma
    Abril, Laura
    Pena, Marta
    Ibarra, Gladys
    Gassiot, Susanna
    Oriol, Albert
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E215 - E215
  • [36] Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: A multicenter retrospective comparative analysis
    Nishimura, Noriko
    Suzuki, Kazuhito
    Tsukada, Nobuhiro
    Nagata, Yasuyuki
    Okaduka, Kiyoshi
    Mishima, Yuko
    Yokoyama, Masahiro
    Nishiwaki, Kaichi
    Ishida, Tadao
    Yano, Shingo
    Terui, Yasuhito
    Suzuki, Kenshi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E214 - E215
  • [37] Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma
    Moreau, Philippe
    Giralt, Sergio A.
    LEUKEMIA RESEARCH, 2012, 36 : S13 - S18
  • [38] Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma
    M Cavo
    L Pantani
    A Pezzi
    M T Petrucci
    F Patriarca
    F Di Raimondo
    G Marzocchi
    M Galli
    V Montefusco
    E Zamagni
    B Gamberi
    P Tacchetti
    A Brioli
    A Palumbo
    P Sonneveld
    Leukemia, 2015, 29 : 2429 - 2431
  • [39] Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma
    Cavo, M.
    Pantani, L.
    Pezzi, A.
    Petrucci, M. T.
    Patriarca, F.
    Di Raimondo, F.
    Marzocchi, G.
    Galli, M.
    Montefusco, V.
    Zamagni, E.
    Gamberi, B.
    Tacchetti, P.
    Brioli, A.
    Palumbo, A.
    Sonneveld, P.
    LEUKEMIA, 2015, 29 (12) : 2429 - 2431
  • [40] IFM guidelines on induction and maintenance for patients with newly diagnosed transplant eligible multiple myeloma
    Macro, Margaret
    HEMATOLOGIE, 2019, 25 (01): : 30 - 40
12345